Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with
standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine,
FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine